EGFR and lung carcinoma: This result was compatible with Zhang et al.’s study (11) of 122 lung cancer patients and 147 controls, reporting a 2.67 (95% CI: 1.17–6.08) odds ratio of the EGFR Q787Q polymorphism in lung cancer.